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Abstract: The plant Sclerochloa dura is traditionally used in South-East Serbia 
to treat menstrual disorders characterized by pain and excessive bleeding. 
According to statements of subjects, a reduction in bleeding and pain is expe-
rienced shortly after oral intake. The focus of this investigation was to deter-
mine the inhibitory effects of the plant on the arachidonic acid (AA) cascade 
along with the spectrophotometric determination of its antioxidant capacity. 
The AA release assay was performed using the human fibroblast-like synovio-
cyte cell line SW982 to determine the AA release and hence phospholipase A2 
(PLA2) activity. The crude extract and subsequent fractions of S. dura inhibit 
IL-1 induced release of AA in a time- and dose-dependent manner in SW982 
cells. The IC50 for the crude extract is 1.5 mg mL-1 at 4 and 24 h of stimulation. 
Treating the cells with 0.22, 0.11 and 0.06 mg mL-1 of a methanolic fraction 
resulted in 97, 91 and 63 % inhibition of AA-release, respectively. One milli-
gram of the crude extract contained 34.78 μg pyrocatechol equivalent phenolic 
content, 22.80 μg quercetin equivalent flavonoid content and an antioxidant 
activity of 70.11 μg α-tocopherol equivalents. The strong inhibitory effects of 
the S. dura extracts on the AA cascade may explain the reported pain- and 
discomfort-relieving effects. 
Keywords: arachidonic acid release assay; cytosolic phospholipase A2 enzyme; 
flavonoid content; free radical scavenging activity; phenolic content; SW 982 
fibroblast-like synoviocytes. 
INTRODUCTION 
Eicosanoids, such as prostaglandins and leukotrienes, are derivatives of the 
ω-6 fatty acid (AA) and act as potent lipid mediators of inflammation.1 AA is 
released by the action of phospholipase A2 (PLA2) enzymes by hydrolysis of the 
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sn-2 ester bond of membrane glycerophospholipids. PLA2 enzymes are primarily 
sorted into five categories; secretry PLA2 (sPLA2), cytosolic PLA2 (cPLA2), 
Ca2+-independent PLA2 (iPLA2), platelet-activating factor acetyl hydrolases 
(PAF-AH) and lysosomal PLA2s.2,3 Alongside the ongoing elucidation of the 
roles of different PLA2 isotypes in physiology or pathophysiology of different 
diseases,4 there is great interest in the development of different PLA2 subtype- 
-specific inhibitors to treat human diseases.5 
Pro-inflammatory cytokines, such as TNF and IL-1β, activate PLA2 enzy-
mes, mainly the arachidonyl specific cPLA2-IVα isotype, resulting in the sub-
sequent release of AA and the generation of pro-inflammatory eicosanoids.6–8 In 
addition, it was previously shown that activated TNF and IL-1β may lead to 
increased transcription of the cyclooxygenase 2 (COX2) and cPLA2-IVα genes, 
further propagating inflammation by increased availability and metabolism of 
AA into pro-inflammatory eicosanoids.8,9 In addition to their association with 
inflammation, increased availability of AA has also been connected with heavy 
menstrual bleeding.10 Prostaglandins, such as PGE2 and PGF2, levels have been 
found to be elevated in the endometrium of women with heavy menstrual bleed-
ing compared to women with normal menses.11,12 Prostaglandins contribute to 
uterus contractions13 and are thought to be a major factor in primary dysme-
norrhea. By targeting the cyclooxygenases (COX1/2) responsible for the enzy-
matic conversion of AA to eicosanoids, non-steroidal anti-inflammatory drugs 
are effective in relieving the pain and discomfort of dysmenorrhea.11 
A good anti-inflammatory activity often accompanies good antioxidant acti-
vity.14,15 There are two basic types of antioxidants available: synthetic and natu-
ral ones. The synthetic antioxidants typically contain phenolic groups as the main 
functionality. The natural antioxidants are mostly obtained from different parts of 
plants and their structural diversity is much larger. They can be either nitrogen-
containing compounds, such as alkaloids, chlorophyll derivatives, amines and 
amino acids, or phenolic compounds, such as tocopherols, flavonoids and pheno-
lic acids. These compounds can act as oxygen scavengers, thereby terminating 
the harmful activity of free radicals.16,17 Flavonoids are considered to be the 
most potent antioxidants. They can delay or inhibit the oxidation of lipids or 
other molecules by inhibiting the propagation of oxidative chain reactions.18 
There has been an increased interest in natural antioxidants from plant materials 
in the recent years.19 
Sclerochloa dura (Linnaeus) P. Beauvois, also known as common hardgrass, 
belongs to family Poaceae Barnhart, which involves more than 700 genera and 
almost 50,000 species. It is an annual plant, with flat leaves and a procumbent or 
erect stem. The inflorescence is a crowded, one-sided series of flattened spike-
lets.20 The plant is a common inhabitant of areas with heavy traffic, e.g., along 
dirty roads, on play yards and walking pathways. It is widely spread in the mode-
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rate climate zone on almost all the continents of the North Hemisphere and was 
introduced to Australia as well.21  
There are only a few published papers in which this plant is mentioned. 
However, none of them deal with its chemical composition or bioactivity. In 
most of the studies, the plant was used as a specimen for the determination of the 
efficiency of various herbicides.22–28 Two papers discuss the phylogeny of cer-
tain grasses, among them S. dura29,30 and one paper deals with the identification 
of prolamines in cereal and grass species, including S. dura.31 
The plant is traditionally used in South-East Serbia for the treatment of 
menstrual disorders, manifested as excessive bleeding and intense pain. Professor 
Aleksandar Igić (Medical faculty, University of Niš, Serbia) in personal corres-
pondence reported that in this region tea or decocts of S. dura have been used by 
women having menstrual disorders. According to the statements of subjects, the 
symptoms were significantly alleviated shortly after intake. The remarkable story 
about the health improving properties of S. dura, together with the lack of pub-
lished data about its chemical composition and bioactivity, was the reason to start 
studying this plant. Therefore, in this study, the aim was to determine the chemi-
cal composition, including free radical scavenging activity, anti-oxidant activity, 
the total phenolic and flavonoid contents of S. dura extract, and its ability to 
inhibit the release of AA. In addition, such properties of S. dura were compared 
with those reported for other plants reported to alleviate menstrual disorders, i.e., 
Wrightia tomentosa32,33 and Dendrophthoe falcata.34 The novel findings pre-
sented herein, forward the plant S. dura as a promising natural source for alle-
viating inflammatory disorders, including menstrual discomfort. 
EXPERIMENTAL 
Plant material 
Sclerochloa dura (whole plant) was collected in June–July 2009 from the city of Niš, 
along the river bank near the Gabrovačka Reka, a creek in Serbia. The plant was identified by 
Bojan Zlatković from the Department of Biology and Ecology, University of Niš, Serbia. A 
specimen of the identified plant was deposited in the Herbarium of the Faculty of Science and 
Mathematics (HMN) of the University of Niš, Serbia (voucher number 6922). Total collected 
weight of the plant was 250 g. The plant material was dried for 10 days in the dark, with 
proper ventilation and at room temperature. The dried plant was kept in a closed plastic bag in 
the dark at room temperature until extraction. 
Reagents and chemicals 
Water used for extraction was obtained from Millipore Elix 5 water purification system, 
n-hexane was from VWR (USA) and methanol was from Fisher Scientific (UK). Recombinant 
human IL-1β was from Roche (UK). Phosphate-buffered saline solution (PBS) was from 
Oxoid (UK). Labelled (5,6,8,9,11,12,14,15-3H)-arachidonic acid (specific activity 180–240 Ci 
mmol-1) and liquid scintillation cocktail Ultima Gold were from NEN Perkin Elmer (USA). 
Dulbecco's Modified Eagle Medium (DMEM), foetal bovine serum (FBS), fatty acid-free 
bovine serum albumin (fBSA), gentamicin and L-glutamine were from Sigma–Aldrich (USA). 
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Potassium acetate, sodium carbonate, 1,1-diphenyl-2-picrylhydrazyl, sodium phosphate, 
α-tocopherol, quercetin, ammonium molybdate, Folin–Ciocalteu reagent, pyrocatechol and 
aluminium nitrate were from Sigma–Aldrich (USA). Sulphuric acid and ascorbic acid were 
from Merck (Germany). 
Extraction procedure 
Aerial parts were crushed into small pieces and extracted by refluxing with water for 20 
min. To enhance extraction, the water extract was sonicated for 15 minutes before and after 
the refluxing (VWR ultrasound cleaner). After 12 h, the extract was filtered (blue ribbon filter 
paper from Schleicher and Schuell) and the volume reduced on a rotavapor (Büchi rotavapor 
R-200). Dry plant sample was obtained by freeze drying (Labconco freeze drier model 
FreeZone 2.5) at –70 °C for 60 h. The crude extract was successively extracted, as shown in 
Scheme 1. 
 
Scheme 1. Separation of crude extract of S. dura. 
The crude extracts and the subsequent fractions (C fraction – water soluble, insoluble in 
methanol, D fraction – methanol extract of crude; water soluble as well) were prepared from 
S. dura. The crude extract was tested for anti-inflammatory and antioxidant activities while 
the subsequent fractions were tested for anti-inflammatory activity only. The S. dura crude 
extract and related fractions were aliquoted in sterile glass vials and stored protected from 
light at 4 °C prior to use. The n-hexane fraction H was not tested for anti-inflammatory 
activity due to the harmful effect of n-hexane on cells. 
Culture and treatment of SW982 cells 
The human fibroblast-like synoviocyte cell line SW982 was purchased from ATCC (UK) 
sub-cultured bi-weekly by routine trypsin detachment and kept in a sub-confluent state. The 
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cells were maintained in DMEM supplemented with 10 % FBS, 0.1 mg mL-1 gentamicin and 
0.3 mg mL-1 L-glutamine in a humidified 10 % CO2 atmosphere at 37 °C. For AA release, 
5×105 cells were seeded per well in a 48-well per plate format. Cells were cultivated until 2 
days post-confluency, serum starved and labelled with 3H-AA in serum-free DMEM over-
night and processed at day 3 post-confluence to ensure differentiation and synchronization of 
the cells. The experiments were performed in serum-free DMEM in triplicates of the wells 
and repeated three times. In all experiments, untreated cells without inducing agents or plant 
extract were included for unstimulated control; distilled water was included for vehicle con-
trol. Following the treatments, the cells were routinely microscopically observed to monitor 
possible effects on cell morphology, integrity and viability. 
Arachidonic acid release assay 
The AA release assay determines the amount of AA released from SW982 cells stimul-
ated with IL-1β. AA release corresponds to the activation of PLA2-enzymes that cleave off the 
AA in the sn-2 position of the phospholipid. In the presence of inhibiting compound(s), the 
release of AA is reduced, which is taken as evidence that the compound(s) target some level 
in the arachidonyl cascade, such as the PLA2 enzymes.7-9 
At 2 days post-confluency, the SW982 cells were serum-starved and labelled overnight 
with 3H-AA (0.4 µCi mL-1) in serum-free DMEM. Prior to the addition of the S. dura extract 
or related fractions, the cells were washed with PBS containing fBSA (2.0 mg mL-1) in order 
to remove unincorporated radioactivity. The cells were pre-treated with various dilutions of 
the crude extract and subsequent fractions (0–20 % extract in serum-free DMEM, 1 h pre-
incubation) followed by the addition of IL-1β (10 ng mL-1) to mimic an inflammatory situ-
ation. After 4 and 24 h of IL-1β stimulation, the supernatants were cleared of detached cells 
by centrifugation (13000 rpm, 10 min). The cellular release of 3H-AA was determined by 
liquid scintillation counting in an LS 6500 Multi-Purpose Scintillation Counter, Beckman 
Coulter, Inc. (USA). The adherent cells were dissolved in 1.0 M NaOH in order to determine 
by liquid scintillation counting the 3H-AA incorporated in the cells. The results are given as 
released 3H-AA in the supernatants relative to total 3H-AA incorporated in the cells. 
Total phenolic content determination 
The total soluble phenolic content of the plant extract was determined with Folin–Cio-
calteu reagent using pyrocatechol as a standard.35,36 An aliquot of 5.0 mg of the dry plant 
extract was dissolved in 20.0 mL of distilled water in an Erlenmeyer flask. The solution was 
diluted to 46.0 mL by the addition of distilled water. Folin–Ciocalteu reagent (1 mL) was 
added to the solution and mixture was shaken vigorously. After 3 min, 3.0 mL of 2 % sodium 
carbonate solution was added. The flask was covered with aluminium foil to protect the com-
plex from possible effects of light. Flask was shaken occasionally for 2 h at room temperature. 
The absorbance was measured at 760 nm37,38 using a UV mini-1240 – Shimadzu (Tokyo, 
Japan) spectrophotometer. A standard curve was plotted using pyrocatechol as a standard and 
the total soluble phenolic contents in the extracts were expressed as μg pyrocatechol equi-
valent, according to the following equation: 
  Y = 0.0533X + 0.0994  (1) 
where Y is the absorbance and X the concentration. 
Total flavonoid content determination 
Dry extract (20.0 mg) was dissolved in 1.0 mL of 80 % ethanol. An aliquot of 0.1 mL 
was taken and diluted to 1.0 mL, giving a concentration of 2.0 mg mL-1. An aliquot of 0.5 mL 
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(1.0 mg) was taken and added to a test tube containing 4.3 mL of 80 % ethanol, 0.1 mL of 
1 M potassium acetate and 0.1 mL of 10 % aluminium nitrate. The mixture was incubated at 
room temperature for 40 min. The absorbance was measured at 415 nm using a UV mini-1240 
– Shimadzu (Tokyo, Japan) spectrophotometer. The total flavonoid content in the plant extract 
was expressed as μg quercetin equivalents39-41 using a standard quercetin graph and according 
to the following equation: 
  Y = 0.0494X – 0.0026  (2) 
where Y is the absorbance and X the concentration. 
Antioxidant activity determination 
The antioxidant activity of the extract was determined by the phosphomolybdenum 
method using α-tocopherol as a standard.42,43 One mg of the extract was combined with 2.0 
mL of the reagent (0.6 M sulphuric acid, 28.0 mM sodium phosphate and 4.0 mM ammonium 
molybdate). A blank solution was prepared by mixing 2.0 mL of the reagent solution with the 
appropriate volume of the same solvent used to dissolve the sample. The tubes were capped 
and incubated in water bath at 95 °C for 90 min. The sample and blank were left 30 min to 
cool down to room temperature. The absorbance of the sample was measured against blank 
solution at 695 nm using a UV mini-1240 – Shimadzu (Tokyo, Japan) spectrophotometer. A 
tocopherol graph was plotted by using α-tocopherol as a standard and the total antioxidant 
activity of the plant extract was expressed as μg α-tocopherol equivalents according to the 
following equation: 
  Y = 7.7686X + 1.678  (3) 
where Y is the absorbance and X the concentration. 
Free radical scavenging activity 
The ability of the extract to quench the 1,1-diphenyl-2-picrylhydrazyl radical (DPPH) 
determines the free radical scavenging activity of a plant material.44-46 It is usually expressed 
as the IC50 value37,47,48 (the extract concentration required to inhibit the activity of DPPH· by 
50 %). 
Seven different dilutions of the plant extract were made in 100 % ethanol: 3200, 1600, 
800, 400, 200, 100 and 50 μg mL-1. A volume of 1.0 mL of 0.3 mM solution of DPPH·was 
mixed with 2.5 mL of each dilution. All the solutions were left at room temperature for 30 
min and then the absorption of each was measured at 518 nm using a UV mini-1240 – Shi-
madzu (Tokyo, Japan) spectrophotometer. A negative control was prepared by mixing 2.5 mL 
of ethanol with 1.0 mL of DPPH. The percentage inhibition for all dilutions was determined 
using the following equation: 
  % Inhibition = 100 – 100(Asample – Ablank)/Acontrol (4) 
where Asample is the absorbance of each dilution; Ablank is the absorbance of the dilutions 
without added DPPH·and Acontrol is the absorbance of the solution of DPPH in ethanol. 
The graph between probit of inhibition (a unit of measurement of statistical probability 
based on deviations from the mean of a normal distribution) vs. the log of concentration was 
plotted and the IC50 value of the plant extract was calculated from the graph. 
Statistical analysis 
All values are expressed as mean ± SD. The cellular bioactivity data were analysed by 
the Student’s t-test and results were considered significant at p < 0.05. 
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RESULTS AND DISCUSSION 
Physical properties of the crude extract and subsequent fractions 
As the traditional use of S. dura is reported to be drinking it as a tea, the 
dried plant was crushed into small pieces and extracted by refluxing with water. 
From 40.0 g of the dry aerial plant parts, a yield of 4.36 g (10.9 %) of a dark 
brown coloured crude extract was obtained, whereas 0.48 g (11.0 % relative to 
dry crude) of yellow coloured water soluble fraction C, 2.79 g (64.0 % relative to 
dry crude) of dark brown coloured fraction D soluble in both water and methanol 
and 0.10 g (2.3 % relative to crude) of a transparent hexane-soluble fraction H. In 
summary, about 80 % of the dried plant extract was extractable by water, 
methanol and hexane, whereas 20.2 % of the fraction appeared as a black, insol-
uble residue. The physical properties of the crude extract and the fractions 
obtained from it are given in Table I. 
TABLE I. Colour, yield and solubility of crude extract and subsequent fractions 
Fraction  Colour  Yield, %  Soluble in 
Crude 
C-Fraction 
D-Fraction 
H-Fraction 
Residue 
Brown 
Yellow 
Brown 
Transparent 
Black 
10.9 
11.0a 
64.0a 
2.3a 
20.2a 
Water 
Water 
Water and methanol 
Hexane 
Insoluble 
aRelative to dry crude 
The crude extract of S. dura inhibits the release of arachidonic acid 
The S. dura extract is traditionally used to alleviate menstrual cramping, 
excessive bleeding and pain, processes known to involve eicosanoids such as 
PGE2,13 also recognized as a pro-inflammatory mediator.1. By use of the AA- 
-release assay and the SW982 cell model system, the effect of the extract on the 
availability of AA, the rate-limiting precursor for PGE2 synthesis, was inves-
tigated. As shown in Fig. 1, the crude extract of S. dura inhibits IL-1β induced 
AA release in a dose-dependent manner, with an observed ≈50 % inhibition at 
1.5 mg mL–1 after both 4 and 24 h of stimulation. Hence, the S. dura extract may 
contain anti-convulsive and/or anti-inflammatory compounds that interfere with 
the arachidonic acid cascade. 
The methanolic fraction of S. dura crude extract efficiently inhibits AA-release 
Having shown that the crude S. dura extract inhibited AA-release, the crude 
extract was further fractionated into a water-soluble fraction C, a hexane-soluble 
fraction H and a methanol-soluble fraction D (Scheme 1) in an attempt to identify 
the active compound(s) in S. dura. Both the C and D fraction were tested for their 
bioactivity in the AA-release assay and they inhibited IL-1β induced AA-release 
in a dose-dependent manner, but with different efficacies. The inhibition obs-
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erved for fraction D, when the treatments with 0.22, 0.11 and 0.06 mg mL–1 
resulted in a 97, 91 and 63 % inhibition of AA-release, respectively, was much 
higher than that observed for fraction C (Fig. 2A and B). Moreover, compared to 
the inhibition obtained with the crude extract, fraction D was far more efficient as 
the IC50 value determined for fraction D was in the range of ng mL–1, not mg 
mL–1 as observed for the crude extract. Fraction H was not tested due to the 
harmful effect of n-hexane to cells. This indicated that most of the bioactive 
compound(s) responsible for the inhibition of AA-release were located in the 
methanol-soluble fraction of the crude extract. 
 
Fig. 1. Crude extract of S. dura inhibits IL-1 (10 ng mL-1) induced release of arachidonic acid 
in a time- and dose-dependent manner in SW982 cells. *p < 0.001, **p < 0.02 by Student’s 
t-test (means ± SD of three experiments each performed in triplicate). 
Antioxidant activity, phenolic content, flavonoid content and free radical 
scavenging activity of S. dura crude extract 
After demonstrating that the crude extract of S. dura was effective in inhi-
biting AA-release, the antioxidant capacity of the crude extract was determined 
because a good anti-inflammatory activity often accompanies a good antioxidant 
activity.14,15 The determination of the antioxidant capacity included the quantifi- 
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Fig. 2. Different fractions of the 
S. dura crude extract inhibit IL-1 
(10 ng mL-1, 24 h) induced AA- 
-release in a dose-dependent 
manner, but with varying effi-
cacy: a) the water soluble frac-
tion (C) inhibits AA-release at 
high concentrations and b) the 
methanol soluble fraction (D) 
inhibits AA-release more effici-
ently at lower concentrations. 
*p  < 0.001, **p  < 0.02 by the 
students’ t-test (means ± SD of 
three experiments each per-
formed in triplicate). 
cation of the antioxidant activity, total phenolic content and the total flavonoid 
content by the linear regression method and an estimation of the free radical 
scavenging ability by the DPPH method. The antioxidant activity of the crude 
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extract of S. dura was 70.11 μg equivalents of α-tocopherol, the total soluble 
phenolic content was 34.78 μg pyrocatechol equivalents and the total soluble 
flavonoid content was 22.80 μg quercetin equivalents per milligram of the plant 
extract (Table II). The free radical scavenging activities of several concentrations 
of S. dura extract were determined. The experiment was repeated under same 
conditions to determine the free radical scavenging activity of ascorbic acid, 
which was used as a standard. The IC50 values for the plant extract and ascorbic 
acid were determined by calculating the inhibition values for all used 
concentrations, taking the probit of all inhibition values and plotting them against 
the log of the respective concentrations. The IC50 value for the plant extract was 
846.64 vs. 11.77 μg mL–1 for ascorbic acid. The results showed that radical sca-
venging activities of both ascorbic acid and the plant extract were concentration 
dependent. 
TABLE II. Total antioxidant activity, total soluble phenolic content and total soluble flavo-
noid content in the extract of S. dura compared to D. falcata and W. tomentosa 
Plant 
Total content of soluble 
phenolics, μg 
pyrocatechol equivalent 
mg-1 
Total content of soluble 
flavonoids, μg quercetin 
equivalent mg-1 
Total antioxidant activity, 
μg α-tocopherol 
equivalent mg-1 
S. dura 34.78±0.38 22.80±0.16 70.11±0.66 
W. tomentosa 7.20±0.88 16.90±1.00 4.20±0.03 
D. falcata 38.66±1.86 21.59±1.09 – 
In a quest to determine the antioxidant potency of S. dura, the obtained 
results were compared with the results reported in literature for the aerial parts of 
Dendrophthoe falcata (Loranthaceae) and the leaf extract of Wrightia tomentosa 
(Apocynaceae) (Table II). Both of these plants chosen for comparison have trad-
itional use for the treatment of menstrual disorders,32–34 i.e., a similar ethno-
pharmacology to S. dura. 
The comparison showed that S. dura had a 4.8 times higher total soluble 
phenolic content, a 1.3 times higher quercetin equivalent flavonoid content and a 
17 times higher total antioxidant activity than W. tomentosa.42 A comparison of 
crude extracts of both plants relative to the DPPH scavenging ability of ascorbic 
acid showed that the extract of W. tomentosa was 1.6 times more potent than the 
extract of S. dura.42 On the other hand, there was not much difference in the total 
soluble phenolics and flavonoids content of S. dura and D. falcata.34 The 
limitation in comparing  the antioxidant activity and free radical scavenging 
activity of S. dura and D. falcata was the non-availability of published results of 
the  α-tocopherol equivalent antioxidant activity and DPPH scavenging ability 
compared to ascorbic acid of D. falcata. In summary, the antioxidant capacity of 
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S. dura is similar to that of D. falcata and far better than that of W. tomentosa 
except in terms of its free radical scavenging ability.  
CONCLUSIONS 
The results from the cellular testing of S. dura (crude extract and sub-frac-
tions) in the AA-release assay suggested that the reported pain- and discomfort- 
-relieving effects of the plant may be explained by the strong inhibitory effects 
on the arachidonic acid cascade. By reducing the availability of AA, the synthesis 
of eicosanoids may be reduced accordingly. Moreover, the total soluble phenolics 
and flavonoids contents of S. dura were similar to those of D. falcata but higher 
than those of W. tomentosa. Although S. dura is less effective in the DPPH assay, 
it has higher antioxidant properties compared to W. tomentosa.  
The presence of flavonoid compounds, known for their various pharmaco-
logical activities, a considerably high antioxidant property and the fact that S. 
dura may exert anti-convulsive, anti-inflammatory and pain-relieving properties, 
gives reasons to believe that the use of the plant in traditional medicine has a 
solid chemical background. Identification of the active compound(s) is the next 
step in the study of S. dura, which could, potentially, reveal new drug candidates 
for various indications. 
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Биљка Sclerochloa dura се традиционално користи у југоисточној Србији за олак-
шавање менструалних тегоба, као што су бол и претерано крварење. Према искуству 
корисница, убрзо по узимању биљке, смањује се крварење и бол. Циљ овог испитивања је 
да  се  утврди  инхибиторни  ефекат  биљке  на  активност  каскаде  коју  започиње  арахи-
донска киселина (АА) и да се спектрофотометријски одреди антиоксидативна активност. 
Тест  ослобађања  АА  изведен  је  коришћењем  хумане  ћелијске  линије  синовиоцита 
SW982, која је слична фибробластима, а мерена је активност фосфолипазе А2 (PLA2). 
Сирови екстракт и изоловане фракције S. dura инхибирају отпуштање АА које иницира 
интерлеукин 1, на временски и дозно зависан начин. IC50 сировог екстракта је 1,5 mg 
mL-1 након 4 h, односно 24 h стимулације. Третирање ћелија метанолним екстрактом 
концентрација 0,22, 0,11 и 0,06 mg mL-1 довело је до инхибиције отпуштања АА од 97, 
91, односно 63 %. Један милиграм сировог екстракта је садржао фенолнa једињења која 
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би одговарала 34,78 μg пирокатехола и флавоноида који би били еквивалентни 22,80 μg 
кверцетина.  Антиоксидативна  активност  је  била  еквивалентна  активности 70,11 μg 
α-токоферола. Јак инхибиторни ефекат екстракта S. dura на активацију AA каскаде би 
могао објаснити смањење бола и других неугодних осећаја. 
(Примљено 2. децембра 2013, прихваћено 14. јануара 2014) 
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